Toll Free: 1-888-928-9744

Hepatic Encephalopathy - Pipeline Review, H2 2016

Published: Jul, 2016 | Pages: 64 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Hepatic Encephalopathy - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Hepatic Encephalopathy - Pipeline Review, H2 2016', provides an overview of the Hepatic Encephalopathy pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Hepatic Encephalopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hepatic Encephalopathy and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hepatic Encephalopathy
- The report reviews pipeline therapeutics for Hepatic Encephalopathy by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Hepatic Encephalopathy therapeutics and enlists all their major and minor projects
- The report assesses Hepatic Encephalopathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Hepatic Encephalopathy

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Hepatic Encephalopathy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hepatic Encephalopathy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Hepatic Encephalopathy Overview 7 Therapeutics Development 8 Pipeline Products for Hepatic Encephalopathy - Overview 8 Hepatic Encephalopathy - Therapeutics under Development by Companies 9 Hepatic Encephalopathy - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Unknown Stage Products 13 Hepatic Encephalopathy - Products under Development by Companies 14 Hepatic Encephalopathy - Companies Involved in Therapeutics Development 15 Alfa Wassermann S.p.A 15 Cosmo Pharmaceuticals S.p.A 16 Horizon Pharma Plc 17 KannaLife Sciences, Inc. 18 Ocera Therapeutics, Inc. 19 Rebiotix Inc. 20 Spherium Biomed S.L. 21 Umecrine Cognition AB 22 Hepatic Encephalopathy - Therapeutics Assessment 23 Assessment by Monotherapy Products 23 Assessment by Target 24 Assessment by Mechanism of Action 26 Assessment by Route of Administration 28 Assessment by Molecule Type 30 Drug Profiles 32 glycerol phenylbutyrate - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 GR-3027 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 KLS-13019 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 ornithine phenylacetate - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 RBX-2477 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 rifamycin CR - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 rifaximin - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 THDP-17 - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 Hepatic Encephalopathy - Dormant Projects 52 Hepatic Encephalopathy - Product Development Milestones 53 Featured News & Press Releases 53 Apr 15, 2016: Ocera Therapeutics Announces Presentation of Two Preclinical Studies Further Supporting Its Ammonia Scavenger OCR-002 at The International Liver Congress 2016 of the European Association for the Study of the Liver (EASL) 53 Apr 11, 2016: Ocera Therapeutics Announces Publication of Promising Preclinical Data in Support of Its Ammonia Scavenger OCR-002 in the Journal of Hepatology 54 Jan 08, 2016: Ocera Announces Complete Plasma Data From Pilot Phase 1 Study for Orally-Available OCR-002 in Development for the Prevention of Chronic Hepatic Encephalopathy 54 Dec 09, 2015: Umecrine Cognition Announces Grant Of a US Patent Protecting Its Lead Candidate Drug GR3027 55 Nov 16, 2015: Ocera Announces Positive Phase 1 Results for Oral OCR-002 in Development for the Prevention of Chronic Hepatic Encephalopathy 56 Sep 16, 2015: Ocera Initiates Phase 1 Clinical Trial of Oral Drug Candidate OCR-002 for Prevention of Hepatic Encephalopathy 57 Aug 19, 2015: Umecrine Cognition announces the publication of preclinical results of the candidate drug GR3027 aimed for the treatment of hepatic encephalopathy 58 Aug 11, 2015: Kannalife Sciences Discusses Orphan Drug Opportunity for KLS-13019 58 Apr 20, 2015: Lupin Launches Zaxine in Canada 59 Apr 01, 2015: Ocera Completes Interim Analysis of OCR-002 in Phase 2b STOP-HE Study for the Treatment of Acute Hepatic Encephalopathy 59 Sep 18, 2014: Salix Secures Additional Intellectual Property Relating to Rifaximin 60 Sep 12, 2014: Lupin and Salix Announce Exclusive Distribution Agreement for Zaxine in Canada 60 Feb 25, 2014: Hyperion Therapeutics Announces the Publication of Phase 2 Results of Glycerol Phenylbutyrate for the Treatment of Hepatic Encephalopathy in Hepatology 61 Feb 14, 2014: Luxembourg National Health Fund Approves Reimbursement Of Xifaxan 550 61 Feb 04, 2014: Salix Pharmaceuticals Announces Issuance Of U. S. Patent For Rifaximin 62 Appendix 63 Methodology 63 Coverage 63 Secondary Research 63 Primary Research 63 Expert Panel Validation 63 Contact Us 63 Disclaimer 64
List of Tables
Number of Products under Development for Hepatic Encephalopathy, H2 2016 8 Number of Products under Development by Companies, H2 2016 9 Comparative Analysis by Late Stage Development, H2 2016 10 Comparative Analysis by Clinical Stage Development, H2 2016 11 Comparative Analysis by Early Stage Development, H2 2016 12 Comparative Analysis by Unknown Stage Development, H2 2016 13 Products under Development by Companies, H2 2016 14 Hepatic Encephalopathy - Pipeline by Alfa Wassermann S.p.A, H2 2016 15 Hepatic Encephalopathy - Pipeline by Cosmo Pharmaceuticals S.p.A, H2 2016 16 Hepatic Encephalopathy - Pipeline by Horizon Pharma Plc, H2 2016 17 Hepatic Encephalopathy - Pipeline by KannaLife Sciences, Inc., H2 2016 18 Hepatic Encephalopathy - Pipeline by Ocera Therapeutics, Inc., H2 2016 19 Hepatic Encephalopathy - Pipeline by Rebiotix Inc., H2 2016 20 Hepatic Encephalopathy - Pipeline by Spherium Biomed S.L., H2 2016 21 Hepatic Encephalopathy - Pipeline by Umecrine Cognition AB, H2 2016 22 Assessment by Monotherapy Products, H2 2016 23 Number of Products by Stage and Target, H2 2016 25 Number of Products by Stage and Mechanism of Action, H2 2016 27 Number of Products by Stage and Route of Administration, H2 2016 29 Number of Products by Stage and Molecule Type, H2 2016 31 Hepatic Encephalopathy - Dormant Projects, H2 2016 52



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify